Mon, Dec 23, 2024 13:05 CET Report this content Medivir will present final safety and efficacy data from its phase Ib/IIa liver cancer study of fostrox in combination with Lenvima at the EASL Liver Cancer Summit in Paris, early next year. The data will be shared by Dr. …
